1. Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis. (2nd September 2020) Authors: Emery, P; Suh, C-H; Weinblatt, ME; Smolen, JS; Keystone, EC; Genovese, M; Vencovsky, J; Kay, J; Hong, E; Baek, Y; Ghil, J Journal: Scandinavian journal of rheumatology Issue: Volume 49:Number 5(2020) Page Start: 361 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis. (2nd September 2020) Authors: Emery, P; Suh, C-H; Weinblatt, ME; Smolen, JS; Keystone, EC; Genovese, M; Vencovsky, J; Kay, J; Hong, E; Baek, Y; Ghil, J Journal: Scandinavian journal of rheumatology Issue: Volume 49:Number 5(2020) Page Start: 361 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P664 SB5 and reference adalimumab show cross-immunogenicity in patients with inflammatory bowel disease or rheumatoid arthritis. (25th January 2019) Authors: Gonçalves, J; Myung, G; Hong, E; Park, M; Jeong, D; Ghil, J Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S451 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗